REDUCE LAP-HF III Corvia Protocol 1701
NCT: NCT03191656 · ACTIVE_NOT_RECRUITING
Brief Summary
This is a post market trial to be conducted at sites in Germany. The device has CE approval in the EU. The purpose of this observational registry is to collect post market data in consecutive patients treated with the IASD System II, to further evaluate efficacy, safety and quality of life outcomes as a new treatment for patients with heart failure in a "real world" practice setting.
Frequently Asked Questions
What is REDUCE LAP-HF III Corvia Protocol 1701?
REDUCE LAP-HF III Corvia Protocol 1701 is a clinical trial registered under NCT03191656. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT03191656?
The current status of NCT03191656 (REDUCE LAP-HF III Corvia Protocol 1701) is: ACTIVE_NOT_RECRUITING.
When did REDUCE LAP-HF III Corvia Protocol 1701 start?
REDUCE LAP-HF III Corvia Protocol 1701 started on 2017-03-12.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.